Efficient Dual siRNA and Drug Delivery Using Engineered Lipoproteoplexes

Che Fu Liu, Raymond Chen, Joseph A. Frezzo, Priya Katyal, Lindsay K. Hill, Liming Yin, Nikita Srivastava, Haresh T. More, P. Douglas Renfrew, Richard Bonneau, Jin Montclare

Research output: Contribution to journalArticle

Abstract

An engineered supercharged coiled-coil protein (CSP) and the cationic transfection reagent Lipofectamine 2000 are combined to form a lipoproteoplex for the purpose of dual delivery of siRNA and doxorubicin. CSP, bearing an external positive charge and axial hydrophobic pore, demonstrates the ability to condense siRNA and encapsulate the small-molecule chemotherapeutic, doxorubicin. The lipoproteoplex demonstrates improved doxorubicin loading relative to Lipofectamine 2000. Furthermore, it induces effective transfection of GAPDH (60% knockdown) in MCF-7 breast cancer cells with efficiencies comparing favorably to Lipofectamine 2000. When the lipoproteoplex is loaded with doxorubicin, the improved doxorubicin loading (∼40 μg Dox/mg CSP) results in a substantial decrease in MCF-7 cell viability.

Original languageEnglish (US)
Pages (from-to)2688-2698
Number of pages11
JournalBiomacromolecules
Volume18
Issue number9
DOIs
StatePublished - Sep 11 2017

Fingerprint

Drug delivery
Doxorubicin
Small Interfering RNA
Bearings (structural)
Cells
Proteins
Molecules
Lipofectamine

ASJC Scopus subject areas

  • Bioengineering
  • Biomaterials
  • Polymers and Plastics
  • Materials Chemistry

Cite this

Liu, C. F., Chen, R., Frezzo, J. A., Katyal, P., Hill, L. K., Yin, L., ... Montclare, J. (2017). Efficient Dual siRNA and Drug Delivery Using Engineered Lipoproteoplexes. Biomacromolecules, 18(9), 2688-2698. https://doi.org/10.1021/acs.biomac.7b00203

Efficient Dual siRNA and Drug Delivery Using Engineered Lipoproteoplexes. / Liu, Che Fu; Chen, Raymond; Frezzo, Joseph A.; Katyal, Priya; Hill, Lindsay K.; Yin, Liming; Srivastava, Nikita; More, Haresh T.; Renfrew, P. Douglas; Bonneau, Richard; Montclare, Jin.

In: Biomacromolecules, Vol. 18, No. 9, 11.09.2017, p. 2688-2698.

Research output: Contribution to journalArticle

Liu, CF, Chen, R, Frezzo, JA, Katyal, P, Hill, LK, Yin, L, Srivastava, N, More, HT, Renfrew, PD, Bonneau, R & Montclare, J 2017, 'Efficient Dual siRNA and Drug Delivery Using Engineered Lipoproteoplexes', Biomacromolecules, vol. 18, no. 9, pp. 2688-2698. https://doi.org/10.1021/acs.biomac.7b00203
Liu CF, Chen R, Frezzo JA, Katyal P, Hill LK, Yin L et al. Efficient Dual siRNA and Drug Delivery Using Engineered Lipoproteoplexes. Biomacromolecules. 2017 Sep 11;18(9):2688-2698. https://doi.org/10.1021/acs.biomac.7b00203
Liu, Che Fu ; Chen, Raymond ; Frezzo, Joseph A. ; Katyal, Priya ; Hill, Lindsay K. ; Yin, Liming ; Srivastava, Nikita ; More, Haresh T. ; Renfrew, P. Douglas ; Bonneau, Richard ; Montclare, Jin. / Efficient Dual siRNA and Drug Delivery Using Engineered Lipoproteoplexes. In: Biomacromolecules. 2017 ; Vol. 18, No. 9. pp. 2688-2698.
@article{c2a847db81a14548905f60e7c357232d,
title = "Efficient Dual siRNA and Drug Delivery Using Engineered Lipoproteoplexes",
abstract = "An engineered supercharged coiled-coil protein (CSP) and the cationic transfection reagent Lipofectamine 2000 are combined to form a lipoproteoplex for the purpose of dual delivery of siRNA and doxorubicin. CSP, bearing an external positive charge and axial hydrophobic pore, demonstrates the ability to condense siRNA and encapsulate the small-molecule chemotherapeutic, doxorubicin. The lipoproteoplex demonstrates improved doxorubicin loading relative to Lipofectamine 2000. Furthermore, it induces effective transfection of GAPDH (60{\%} knockdown) in MCF-7 breast cancer cells with efficiencies comparing favorably to Lipofectamine 2000. When the lipoproteoplex is loaded with doxorubicin, the improved doxorubicin loading (∼40 μg Dox/mg CSP) results in a substantial decrease in MCF-7 cell viability.",
author = "Liu, {Che Fu} and Raymond Chen and Frezzo, {Joseph A.} and Priya Katyal and Hill, {Lindsay K.} and Liming Yin and Nikita Srivastava and More, {Haresh T.} and Renfrew, {P. Douglas} and Richard Bonneau and Jin Montclare",
year = "2017",
month = "9",
day = "11",
doi = "10.1021/acs.biomac.7b00203",
language = "English (US)",
volume = "18",
pages = "2688--2698",
journal = "Biomacromolecules",
issn = "1525-7797",
publisher = "American Chemical Society",
number = "9",

}

TY - JOUR

T1 - Efficient Dual siRNA and Drug Delivery Using Engineered Lipoproteoplexes

AU - Liu, Che Fu

AU - Chen, Raymond

AU - Frezzo, Joseph A.

AU - Katyal, Priya

AU - Hill, Lindsay K.

AU - Yin, Liming

AU - Srivastava, Nikita

AU - More, Haresh T.

AU - Renfrew, P. Douglas

AU - Bonneau, Richard

AU - Montclare, Jin

PY - 2017/9/11

Y1 - 2017/9/11

N2 - An engineered supercharged coiled-coil protein (CSP) and the cationic transfection reagent Lipofectamine 2000 are combined to form a lipoproteoplex for the purpose of dual delivery of siRNA and doxorubicin. CSP, bearing an external positive charge and axial hydrophobic pore, demonstrates the ability to condense siRNA and encapsulate the small-molecule chemotherapeutic, doxorubicin. The lipoproteoplex demonstrates improved doxorubicin loading relative to Lipofectamine 2000. Furthermore, it induces effective transfection of GAPDH (60% knockdown) in MCF-7 breast cancer cells with efficiencies comparing favorably to Lipofectamine 2000. When the lipoproteoplex is loaded with doxorubicin, the improved doxorubicin loading (∼40 μg Dox/mg CSP) results in a substantial decrease in MCF-7 cell viability.

AB - An engineered supercharged coiled-coil protein (CSP) and the cationic transfection reagent Lipofectamine 2000 are combined to form a lipoproteoplex for the purpose of dual delivery of siRNA and doxorubicin. CSP, bearing an external positive charge and axial hydrophobic pore, demonstrates the ability to condense siRNA and encapsulate the small-molecule chemotherapeutic, doxorubicin. The lipoproteoplex demonstrates improved doxorubicin loading relative to Lipofectamine 2000. Furthermore, it induces effective transfection of GAPDH (60% knockdown) in MCF-7 breast cancer cells with efficiencies comparing favorably to Lipofectamine 2000. When the lipoproteoplex is loaded with doxorubicin, the improved doxorubicin loading (∼40 μg Dox/mg CSP) results in a substantial decrease in MCF-7 cell viability.

UR - http://www.scopus.com/inward/record.url?scp=85029332240&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85029332240&partnerID=8YFLogxK

U2 - 10.1021/acs.biomac.7b00203

DO - 10.1021/acs.biomac.7b00203

M3 - Article

C2 - 28686014

AN - SCOPUS:85029332240

VL - 18

SP - 2688

EP - 2698

JO - Biomacromolecules

JF - Biomacromolecules

SN - 1525-7797

IS - 9

ER -